Search

Researchers with the Peter O’Donnell Jr. Brain Institute at UT Southwestern have identified a new protein implicated in cell death that provides a potential therapeutic target that could prevent or delay the progress of neurodegenerative diseases following a stroke.

A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer.

Dr. Stephanie Tow, M.D., completed her first week of providing volunteer care at the Tokyo 2020 Olympics.

UT Southwestern researchers find that humans and mice with pancreatitis are deficient in a stress hormone called FGF21.

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins – molecules that transport fat in blood – which enriches cancer cells with an antioxidant shield to survive stress, according to new research from Children’s Medical Center Research Institute at UT

An artificial intelligence (AI)-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy, a class of treatments that’s only effective in some cases.

Todd Aguilera, M.D., Ph.D., Assistant Professor of Radiation Oncology and member of the Experimental Therapeutics Program in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, has been named one of 11 inaugural Cancer Moonshot Scholars. The national program

Researchers at UT Southwestern Medical Center have been approved for an $18 million funding award from the nonprofit Patient-Centered Outcomes Research Institute (PCORI) to investigate ways to improve postpartum health among primarily low-income Black and Hispanic women.

UT Southwestern physician-scientist Hesham Sadek, M.D., Ph.D., has received the prestigious National Institutes of Health (NIH) Outstanding Investigator Award to support his ongoing research into mechanisms behind heart regeneration that could lead to treatments for heart failure.

UT Southwestern Medical Center is collaborating with Pfizer Inc. to develop RNA enhanced delivery technologies for genetic medicine therapies through the Dallas-based medical center’s Program in Genetic Drug Engineering.